Elisabetta Degasperi

2.4k total citations
82 papers, 1.2k citations indexed

About

Elisabetta Degasperi is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Elisabetta Degasperi has authored 82 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Hepatology, 74 papers in Epidemiology and 4 papers in Molecular Biology. Recurrent topics in Elisabetta Degasperi's work include Hepatitis C virus research (69 papers), Liver Disease Diagnosis and Treatment (63 papers) and Hepatitis B Virus Studies (38 papers). Elisabetta Degasperi is often cited by papers focused on Hepatitis C virus research (69 papers), Liver Disease Diagnosis and Treatment (63 papers) and Hepatitis B Virus Studies (38 papers). Elisabetta Degasperi collaborates with scholars based in Italy, France and United States. Elisabetta Degasperi's co-authors include Alessio Aghemo, Massimo Colombo, Pietro Lampertico, Roberta D’Ambrosio, R. Soffredini, Massimo Colombo, Marta Borghi, Riccardo Perbellini, Maria Grazia Rumi and Angelo Sangiovanni and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Hepatology.

In The Last Decade

Elisabetta Degasperi

76 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elisabetta Degasperi Italy	19	918	887	102	90	79	82	1.2k
Sara Cmet Italy	15	666 0.7×	559 0.6×	95 0.9×	91 1.0×	71 0.9×	35	1.0k
Valeria Piazzolla Italy	16	910 1.0×	861 1.0×	70 0.7×	121 1.3×	82 1.0×	43	1.1k
Stephen Pianko Australia	19	845 0.9×	862 1.0×	108 1.1×	92 1.0×	92 1.2×	35	1.1k
Eduardo B. Martins United States	17	1.1k 1.2×	1.0k 1.1×	72 0.7×	133 1.5×	114 1.4×	42	1.4k
Nai‐Jen Hou Taiwan	16	917 1.0×	943 1.1×	45 0.4×	65 0.7×	47 0.6×	38	1.1k
Xiumei Chi China	18	504 0.5×	512 0.6×	175 1.7×	80 0.9×	213 2.7×	53	917
Efsevia Albanis United States	11	882 1.0×	919 1.0×	96 0.9×	132 1.5×	73 0.9×	11	1.1k
Mei‐Hsuan Lee Taiwan	16	556 0.6×	518 0.6×	99 1.0×	43 0.5×	40 0.5×	43	791
Alessia Ciancio Italy	24	1.8k 1.9×	1.8k 2.1×	140 1.4×	180 2.0×	41 0.5×	101	2.2k
Bradley Freilich United States	9	655 0.7×	576 0.6×	88 0.9×	101 1.1×	80 1.0×	14	828

Countries citing papers authored by Elisabetta Degasperi

Since Specialization

Citations

This map shows the geographic impact of Elisabetta Degasperi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabetta Degasperi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabetta Degasperi more than expected).

Fields of papers citing papers by Elisabetta Degasperi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabetta Degasperi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabetta Degasperi. The network helps show where Elisabetta Degasperi may publish in the future.

Co-authorship network of co-authors of Elisabetta Degasperi

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabetta Degasperi. A scholar is included among the top collaborators of Elisabetta Degasperi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabetta Degasperi. Elisabetta Degasperi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Salpini, Romina, Elisabetta Degasperi, Lorenzo Piermatteo, et al.. (2025). HBsAg Isoforms as Innovative Biomarkers in Predicting Virological Response to Bulevirtide in Patients With Chronic Hepatitis D. Liver International. 45(5). e70094–e70094.

Degasperi, Elisabetta, et al.. (2025). Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024. Liver International. 45(7). e70189–e70189. 3 indexed citations

Degasperi, Elisabetta, et al.. (2024). Advances in hepatitis delta research: emerging insights and future directions. Sexually Transmitted Infections. 100(5). 310–317.

Iavarone, Massimo, Riccardo Perbellini, Sara Uceda Renteria, et al.. (2024). ASAP score may predict HCC recurrence after complete radiological response to locoregional treatments. Digestive and Liver Disease. 56. S89–S89. 1 indexed citations

Caviglia, Gian Paolo, Piero Fariselli, Roberta D’Ambrosio, et al.. (2024). Development and Validation of a PIVKA‐II‐Based Model for HCC Risk Stratification in Patients With HCV‐Related Cirrhosis Successfully Treated With DAA. Alimentary Pharmacology & Therapeutics. 61(3). 538–549. 2 indexed citations

Graf, Christiana, Roberta D’Ambrosio, Elisabetta Degasperi, et al.. (2024). Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure. JHEP Reports. 6(3). 100994–100994. 6 indexed citations

Renteria, Sara Uceda, Elisabetta Degasperi, Marta Borghi, et al.. (2024). Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods. Liver International. 44(3). 831–837. 4 indexed citations

Degasperi, Elisabetta, Sara Uceda Renteria, Marta Borghi, et al.. (2023). Pretreatment and on-therapy HDV RNA levels predict response to Bulevirtide monotherapy in HDV compensated cirrhotic patients treated up to 96 weeks. Journal of Hepatology. 78. S1159–S1159. 1 indexed citations

Loglio, Alessandro, Giulia Tosetti, Elisabetta Degasperi, et al.. (2023). Long‐term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years. Alimentary Pharmacology & Therapeutics. 57(12). 1407–1416. 1 indexed citations

10.

Degasperi, Elisabetta, F. Facchetti, Caroline Scholtès, et al.. (2023). Kinetics of hepatitis B core related antigen in patients with compensated HDV cirrhosis treated with Bulevirtide monotherapy for 72 weeks: a single-center study. Journal of Hepatology. 78. S1170–S1170. 1 indexed citations

11.

Degasperi, Elisabetta, Sara Uceda Renteria, Marta Borghi, et al.. (2022). Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. Journal of Hepatology. 77(6). 1525–1531. 42 indexed citations

12.

Shekhtman, Louis, Harel Dahari, Scott J. Cotler, et al.. (2022). Most patients with advanced cirrhosis treated with bulevirtide monotherapy have a non-monophasic HDV RNA decline patterns: an interim kinetic analysis of real-life setting. Journal of Hepatology. 77. S874–S874. 1 indexed citations

13.

Iavarone, Massimo, Giulia Tosetti, F. Facchetti, et al.. (2022). Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study. Digestive and Liver Disease. 55(2). 160–168. 13 indexed citations

14.

Colucci, Giuseppe, Federica Invernizzi, Sara Uceda Renteria, et al.. (2021). The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles. Viral Immunology. 34(8). 542–551. 3 indexed citations

15.

D’Ambrosio, Roberta, Elisabetta Degasperi, Marta Borghi, et al.. (2021). Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. Journal of Hepatology. 76(2). 302–310. 49 indexed citations

16.

D’Ambrosio, Roberta, Elisabetta Degasperi, Massimo Iavarone, et al.. (2018). Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3 year study. Journal of Hepatology. 68. S529–S529. 4 indexed citations

17.

D’Ambrosio, Roberta, Elisabetta Degasperi, Massimo Colombo, & Alessio Aghemo. (2017). Direct-acting antivirals: the endgame for hepatitis C?. Current Opinion in Virology. 24. 31–37. 70 indexed citations

18.

Degasperi, Elisabetta, Alessio Aghemo, & Massimo Colombo. (2015). Daclatasvir for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy. 16(17). 2679–2688. 6 indexed citations

19.

Clark, Paul J., Alessio Aghemo, Elisabetta Degasperi, et al.. (2013). Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. Journal of Viral Hepatitis. 20(12). 858–866. 27 indexed citations

20.

Prati, Gian Maria, Alessio Aghemo, Maria Grazia Rumi, et al.. (2011). Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. Journal of Hepatology. 56(2). 341–347. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact